Mackie Research lowered its price target for Cipher Pharmaceuticals (TSX:CPH) to $1 (Canadian) from $2.30, citing a delay in the out-licensing of its Canadian assets because of a dispute with Bausch Health (NYSE:BHC) regarding constipation med, Trulance. See Cipher Pharmaceuticals Inc. Reg (PHE.SG) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. See todayâs analyst top recommended stocks >> The company has a one-year high of $1.15 and a one-year low of $0.30. 19, 2021Corporate Participants: Craig Mull â Interim Chief Executive Officer Scott Langille â Chief Financial Officer Analysts: Douglas Loe â Leede Jones Gable â Analyst See CIPHER PHARMACEUTICALS INC (CPH.TO) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Cipher Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. See todayâs analyst top recommended stocks >> CRH Medical (CRHM) Bloom Burton analyst David Martin Buy $4.00 The best long-term & short-term Cipher Pharmaceuticals ⦠View analyst ratings, recommendations and price targets for Cipher Pharmaceuticals Inc. (CPH). Cipher Pharmaceuticals (CPHRF) Echelon Wealth Partners analyst Douglas Loe maintained a Buy rating on Cipher Pharmaceuticals on April 21 and set a price target of C$3.00 . This is Langilleâs first transaction since reporting a Buy transaction on TSE:SVA back in April 2017 In addition to Scott Langille, 2 other CPHRF executives ⦠Cipher Pharmaceuticals Inc Key Recent Developments May 07,2020: Cipher Pharmaceuticals reports Ffrst quarter 2020 financial results Mar 25,2020: Cipher Pharmaceuticals reports fourth quarter and ⦠Cipher Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $1.15. Cipher Pharmaceuticals Inc. Q4 2020 earnings call dated Mar. See CIPHER PHARMACEUTICALS INC (CPH.TO) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Cipher Pharmaceuticals Inc. Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. Cipher Pharmaceuticals Inc. analyst estimates, including CPHRF earnings per share estimates and analyst recommendations. Learn about CPHRF (PINX) with our data and independent analysis including price, star rating, valuation, dividends, and financials. Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. * Cipher Pharmaceuticals Inc (CPHRF) - QTRLY TOTAL REVENUE INCREASED 3.4% TO $6.1 MILLION FROM $5.9 MILLION.) Latest Analyst Research & Price Targets for Cipher Pharmaceuticals Inc (CPH-T). Price target in 14 days: 1.649 CAD. Craig Mull, ⦠The analyst consensus price target for Cipher Pharmaceuticals over the next year is $18.56, which is about 40 per cent above where it's currently trading, at around $13.30. Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Dedication to our vision is paramount to our success as we expand our product offerings and presence in North America. At Simply Wall St, we have a full range of analyst estimates for Cipher Pharmaceuticals going out to 2023, and you can see them free on our platform here.. Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or ⦠Tip: Try a valid symbol or a specific company name for relevant results Tip: Try a valid symbol or a specific company name for relevant results It acquires products and compounds for treatment of various medical needs. View the latest Cipher Pharmaceuticals Inc. (CPH) stock price, news, historical charts, analyst ratings and financial information from WSJ. The companyâs shares closed last ⦠CIPHER PHARMACEUTICALS INC. analysts consensus, targets, ratings and recommendations | Toronto Stock Exchange: CPH | Toronto Stock Exchange - ⦠It operates in the specialty pharmaceuticals segment. 11:10a Vera Therapeutics Makes Its Debut After Others Delay IPOs Skip to main content Support Quality Journalism. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident Cipher Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $1.90, representing a 99.8% upside. Currently, the most bullish analyst values Jazz Pharmaceuticals at US$235 per share, while the most bearish prices it at US$176. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. In a report issued on August 14, Bloom Burton also maintained a Buy rating on the stock About Cipher Pharmaceuticals Inc Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. Analyst Ratings for Cipher Pharmaceuticals Inc (CPH.TO) provide recommendations made by outside industry experts. Cipher is headquartered in Mississauga, Ontario, Canada Cipher Pharmaceuticals Inc Key Recent Developments Mar 18,2021: Cipher Pharmaceuticals Reports Fourth Quarter and Full ⦠Find the latest analyst research for Cipher Pharmaceuticals Inc (CPHRF) at Nasdaq.com. CPH.CA updated stock price target summary. The Company has a portfolio of commercial and late-stage products. Cipher Pharmaceuticals Inc (CPHRF): * CIPHER PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS. Cipherâs board of directors has decades of experience and a proven record of success in all facets needed to efficiently develop and commercialize dermatology products. Cipher Pharmaceuticals Stock Forecast, CPH stock price prediction. Cipher Pharmaceuticals Schedules Q1 2021 Earnings Release and Conference Call Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced it will release its Q1 2021 financial results after market close on Thursday, May 13, 2021. Currently, Cipher Pharmaceuticals has an average volume of 10.93K. Cipher Pharmaceuticals Inc. ("Cipher" or "the Company") today announced its financial and operating results for the three months ended March 31, 2021. Today, the Chief Financial Officer of Cipher Pharmaceuticals (CPHRF â Research Report), Scott Langille, bought shares of CPHRF for $31.25K.
Me, Myself And Irene, Does Kraken Report To Irs Reddit, Arsenal Club Doctor Salary, Atp Estoril 2021, Cat Jersey Nba,